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Abstract
Context: There is contradictory information regarding the prognostic importance of adipocytokines, hepatic and
inflammatory biomarkers on the incidence of type 2 diabetes. The objective was to assess the prognostic relevance of
adipocytokine and inflammatory markers (C-reactive protein – CRP; interleukin-1beta – IL-1b; interleukin-6– IL-6; tumour
necrosis factor-a – TNF-a; leptin and adiponectin) and gamma-glutamyl transpeptidase (cGT) on the incidence of type 2
diabetes.
Methods: Prospective, population-based study including 3,842 non-diabetic participants (43.3% men, age range 35 to
75 years), followed for an average of 5.5 years (2003–2008). The endpoint was the occurrence of type 2 diabetes.
Results: 208 participants (5.4%, 66 women) developed type 2 diabetes during follow-up. On univariate analysis, participants
who developed type 2 diabetes had significantly higher baseline levels of IL-6, CRP, leptin and cGT, and lower levels of
adiponectin than participants who remained free of type 2 diabetes. After adjusting for a validated type 2 diabetes risk
score, only the associations with adiponectin: Odds Ratio and (95% confidence interval): 0.97 (0.64–1.47), 0.84 (0.55–1.30)
and 0.64 (0.40–1.03) for the second, third and forth gender-specific quartiles respectively, remained significant (P-value for
trend= 0.05). Adding each marker to a validated type 2 diabetes risk score (including age, family history of type 2 diabetes,
height, waist circumference, resting heart rate, presence of hypertension, HDL cholesterol, triglycerides, fasting glucose and
serum uric acid) did not improve the area under the ROC or the net reclassification index; similar findings were obtained
when the markers were combined, when the markers were used as continuous (log-transformed) variables or when gender-
specific quartiles were used.
Conclusion: Decreased adiponectin levels are associated with an increased risk for incident type 2 diabetes, but they seem
to add little information regarding the risk of developing type 2 diabetes to a validated risk score.
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Introduction
The prevalence of type 2 diabetes is increasing worldwide [1].
Interleukin-1 beta (IL-1b), interleukin 6 (IL-6), and C-reactive
protein (CRP) are three inflammatory markers which have been
shown to predict the development of diabetes [2,3,4], although this
association is interpreted controversially [5,6]. Conversely, tumour
necrosis factor alpha (TNF-a) has not been reported to affect
diabetes development [3]. Adipocytokines also contribute to the
development of type 2 diabetes; for instance, leptin increases [7],
while adiponectin decreases [8] the risk of type 2 diabetes. Finally,
recent studies have suggested that gamma-glutamyl transpeptidase
(cGT) might be a better predictor of type 2 diabetes than
inflammatory markers [9,10,11]. Still, although most studies
included age, gender and anthropometric data (body mass index
or waist circumference), other variables such as alcohol consump-
tion or family history of diabetes were not considered. Recently,
several type 2 diabetes risk scores have been proposed, based on
clinical data alone, or on clinical variables in combination with
biological parameters [12,13].
In a previous study, we have demonstrated that the Kahn
(clinical + biological) risk score [14] adequately predicted the type
2 diabetes incidence within the CoLaus cohort [13]. The aim of
this prospective observational study was twofold: 1) to assess the
associations of various adipocytokines, hepatic and inflammatory
markers with the incidence of type 2 diabetes; and 2) to assess the
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value of adding these markers into an existing type 2 diabetes risk
score to possibly improve the prediction of type 2 diabetes, as
recommended by current guidelines [15,16]. To our knowledge,
there is little information about whether adipocytokines, hepatic
and inflammatory markers might improve existing type 2 diabetes
risk scores.
Methods
Recruitment
The CoLaus Study was designed to assess the prevalence of
cardiovascular risk factors (hypertension, diabetes, dyslipidemia,
obesity and smoking) and to identify new molecular determinants
of these risk factors in the Caucasian population from Lausanne
(Switzerland). The study was approved by the Institutional Ethics
Committee of the University of Lausanne and all participants
provided written informed consent into the protocol.
The sampling procedure of the CoLaus Study has been
described previously [17]. In summary, a simple, nonstratified
random sample of the overall population of Lausanne was drawn.
The following inclusion criteria were applied: (a) written informed
consent; (b) willingness to take part in the examination and to
provide blood samples and (c) Caucasian origin. Recruitment
began in June 2003 and ended in May 2006. Participation rate
was 41% with 6,188 Caucasian participants (3,251 women and
2,937 men) taking part in the genetic study.
All participants were seen in the morning after an overnight fast
(minimum fasting time 8 hours).
Baseline data collection
The participants were asked about their personal and family
history of diabetes and hypertension as well as their treatment.
Body weight and height were measured with participants
standing without shoes in light indoor clothes. Body weight was
measured in kilograms to the nearest 100 g using a SecaH scale,
which was calibrated regularly. Height was measured to the
nearest 5 mm using a SecaH height gauge. Waist circumference
was measured with a non-stretchable tape over the unclothed
abdomen at the narrowest point between the lowest rib and the
iliac crest. Two measures were made and the mean (expressed in
centimetres) was used for analyses. Blood pressure and resting
pulse were measured thrice on the left arm, with an appropriately
sized cuff, after a rest of at least 10 minutes in the seated position
using an OmronH HEM-907 automated oscillometric sphygmo-
manometer. The average of the last two blood pressure
measurements was used for analyses. Hypertension was defined
as systolic blood pressure $140 mm Hg and/or diastolic blood
pressure $90 mm Hg or presence of antihypertensive drug
treatment.
Venous blood samples (50 mL) were drawn in the fasting state.
Serum was preferred to plasma as it has been shown that different
anticoagulants may affect absolute cytokine levels differently [18].
It has also been stated that cytokine levels in a single blood sample
may be useful biomarkers of inflammation in population-based
studies of obesity-related diseases [18]. Serum samples were kept at
280uC for five years before assessment of the other cytokines and
sent on dry ice to the laboratory. Adiponectin was assessed by
ELISA (R&D Systems, Inc, Minneapolis, USA) with a maximum
inter-assay CV of 8.3% and a maximum intra-assay CV of 8.3%.
Leptin was assessed by ELISA (American Laboratory Products
Company, Windham, USA) with a maximum inter-assay CV of
12.8% and a maximum intra-assay CV of 5.8%; glucose by
glucose dehydrogenase (2.1%–1.0%); cGT by the optimized
standard method according to the International Federation of
Clinical Chemistry, at 37uC (1.6%–0.4%); HDL-cholesterol by
CHOD-PAP + PEG + cyclodextrin (3.6%–0.9%); triglycerides by
GPO-PAP (2.9%–1.5%) and uric acid by uricase-PAP (1.0%–
0.5%).
High sensitive CRP (hs-CRP) was assessed by immunoassay and
latex HS (IMMULITE 1000–High, Diagnostic Products Corpo-
ration, LA, CA, USA) with maximum intra- and interbatch
coefficients of variation of 1.3% and 4.6%, respectively. For
cytokine measurement, serum was preferred to plasma as it has
been shown that different anticoagulants may affect absolute
cytokine levels differentially [19]. Serum samples were kept at
280uC before assessment of the other cytokines and sent on dry
ice to the laboratory. Cytokine levels were measured using a
multiplexed particle-based flow cytometric cytokine assay [20], a
methodology also used in other studies [21]. Milliplex kits were
purchased from Millipore (Zug, Switzerland). The procedures
closely followed the manufacturer’s instructions. The analysis was
conducted using a conventional flow cytometer (FC500 MPL,
BeckmanCoulter, Nyon, Switzerland). Lower detection limits for
IL-1b, IL-6 and TNF-a were 0.2 ng/l. A good agreement between
signal and cytokine was found within the assay range (R2$0.99).
Intra and inter-assay coefficients of variation were 15% and 16.7%
for IL-1b, 16.9% and 16.1% for IL-6 and 12.5% and 13.5% for
TNF-a, respectively. Repeated measurements were conducted in
80 subjects randomly drawn from the initial sample; Spearman
rank correlations between duplicate measurements were 0.91, 0.96
and 0.89 for IL-1b, IL-6 and TNF-a (all p,0.001).
Follow-up data collection
In their original consent letter, participants were informed of a
potential follow-up study. Approximately 96% gave permission
and were re-contacted. Prior to the follow-up interview, partici-
pants received the detailed information letter and consent forms.
The follow-up visit was performed five years after the collection
of baseline data. Similarly to the baseline evaluation, the somatic
investigation included an interview, a physical exam, blood
analysis and a set of questionnaires. At the time of the analysis,
data for 4,602 participants was available.
In both evaluation periods (baseline and follow-up) diabetes was
defined as fasting plasma glucose (FPG) $7.0 mmol/L and/or
presence of oral hypoglycemic or insulin treatment [22]. Type 2
diabetes was defined in case of diabetes without self-reported type
1 diabetes. Subjects who presented with type 1 or type 2 diabetes
at baseline were excluded from the present analysis.
Statistical analysis
Of the initial 4,602 participants with follow-up data, 269 (5.8%)
were excluded because of type 1 or type 2 diabetes at baseline, 85
(1.8%) because of missing fasting glucose data at follow-up and
406 (8.8%) because of missing data for leptin (N= 386) or
adiponectin (N= 20), leaving 3842 participants (83.5%) for
analysis. Excluded participants were less frequently women, were
younger and had lower body mass index and hs-CRP levels than
non-excluded ones, while no significant differences were found
regarding the other biological markers (Table S1).
Statistical analysis was conducted using Stata v.12.1 (Stata
Corp, College Station, TX, USA). Biomarkers were presented as
median and (interquartile range) of measured values, percentage of
values below LOD and percentage of values within each gender-
specific quartile. Many participants had cytokine levels below
LOD (37% for IL-1b, 8.8% for IL-6 and 1.6% for TNF-a).
Undetectable values were included in the first quartile. For
participants with undetectable cytokines levels, a value of half the
LOD was assigned for quantitative analyses [23,24]. Comparisons
Adipocytokines and Risk of Diabetes
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between subjects who developed type 2 diabetes and those who did
not were conducted using Kruskall-Wallis non-parametric test or
chi-square. Association with incident diabetes was analyzed by
logistic regression and the results were expressed for each variable
as odds ratio with 95% confidence interval. Three different models
were tested: 1) adjusting for age and gender; 2) adjusting for age,
gender and body mass index (BMI); and 3) adjusting for a type 2
diabetes risk score [14] validated in the CoLaus cohort [25]. It
includes age, family history of type 2 diabetes, black race (not used
here as all participants are Caucasian), height, waist circumfer-
ence, resting heart rate, presence of hypertension, HDL choles-
terol, triglycerides, fasting glucose and serum uric acid. Age,
gender and BMI were used as covariates because they are
associated with an increased risk for type 2 diabetes. The main aim
of this study was to assess the predictive utility of several
biomarkers regarding the development of type 2 diabetes relative
to a validated risk score for type 2 diabetes.
As measures of overall model fit, we examined the Hosmer-
Lemeshow goodness-of-fit test, the Akaike Information Criterion
(AIC) [26] and the Bayes Information Criterion (BIC) [27]; the
lower the AIC and BIC values, the better the goodness of fit.
The improvement in the predictive ability of this risk score by
inclusion of adipocytokine, hepatic or inflammatory data was
assessed by comparing the areas under the receiver operating
curve (AROC) between the models with and without the
adipocytokine, hepatic or inflammatory marker of interest. Two
AROCs were computed: 1) using the type 2 diabetes risk
predicted by the model as a continuous variable and 2) splitting
the type 2 diabetes risk into two categories (not at risk and at
risk). For this second AROC, a threshold of 23% was used for
sensitivity analyses. This was decided as the original 46%
threshold had been proposed for a 10-year follow-up [14], while
the average follow-up in this study was only 5 years. We also
assessed the sensitivity, specificity, positive and negative predic-
tive values, net reclassification improvement (NRI) and integrated
discrimination improvement (IDI) [28] (with 95% confidence
intervals) for each adipocytokine, hepatic or inflammatory
marker (divided into sex-specific quartiles), using incident
diabetes and the binary variable defined previously, i.e. ‘‘not at
risk’’ (estimated risk ,23%) and ‘‘at risk’’ (estimated risk$23%).
The AUC, NRI and IDI are presented for each adipocytokine,
hepatic or inflammatory marker as recommended [29]. Con-
versely, we did not present continuous NRI as it might not be
and adequate marker of model improvement [30].
Sensitivity analyses were conducted as follows: analyses were
conducted using continuous, log-transformed values instead of
quartiles, and assessing the OR for the increase in one standard
deviation of the log-transformed values. As leptin, adiponectin and
cGT showed considerable variation between men and women, we
also tested the use of sex-specific quartiles for these variables. As it
has been suggested that the simultaneous inclusion of several
markers might improve risk prediction [31,32,33], the improve-
ment in predictive ability was also assessed for the following
combinations: adiponectin and CRP, CRP and cGT, and all
inflammatory markers. Finally, a prospective study suggested that
IL-1b might interact with IL-6, participants with detectable IL-1b
levels and elevated IL-6 levels presenting an increased risk to
develop type 2 diabetes relative to individuals with undetectable
IL-1b levels and increased IL-6 levels [3], a similar analysis was
performed.
Statistical significance was established for p,0.05.
Results
Association between cytokines and incident type 2
diabetes mellitus
During the 5-year follow-up, 208 of the 3842 participants
(5.4%, 95% confidence interval 4.7–6.2) developed type 2
diabetes, corresponding to incidence rate of 9.8 cases per 1,000
persons-year. The levels of adipocytokines, hepatic and inflam-
matory markers in the group who developed type 2 diabetes and in
the group who did not are summarized in Table 1 and
Table S2. Participants who developed type 2 diabetes during
follow-up had significantly higher levels of IL-6, hs-CRP, leptin
and cGT, and lower levels of adiponectin than participants who
remained free from type 2 diabetes. No significant differences were
found for TNF-a and IL-1b.
The association between adipocytokine, hepatic and inflamma-
tory marker levels and incident type 2 diabetes was further
assessed by analysing the risk of developing type 2 diabetes
according to the quartiles of each biological variable. The results
are summarized in Table 2. On bivariate analysis, IL-6, hs-CRP,
leptin and cGT were positively associated with increased risk of
type 2 diabetes; IL-1b and adiponectin were inversely associated
with type 2 diabetes risk. Conversely, no significant association was
found with TNF-a. After multivariate adjustment, only the
positive association with cGT and the negative association with
adiponectin retained their significance (Table 2).
Impact in predictive capacity of a type 2 diabetes
mellitus risk score
The improvement in the predictive ability of this risk score by
inclusion of adipocytokine, hepatic or inflammatory data is
summarized in Tables 3 and 4. Overall, all models fitted to
the data, as indicated by the nonsignificant results of the Hosmer-
Lemeshow test. Conversely, none of the markers led to an
improvement in goodness of fit as indicated by the AIC and BIC.
Also, no improvement in the predictive capacity of the initial
model, as assessed by AROC, was found using type 2 diabetes risk
either as a continuous or a ‘‘not at risk’’ (,23%) and ‘‘at risk’’
($23%) category (Table 3). No significant improvement was
found in sensitivity, specificity, NPV, PPV and NRI for all the
markers studied (Table 4), although the improvement in IDI for
adiponectin was close to statistical significance (p = 0.052).
Conversely, including all markers in the model led to an
improvement in the AROC (Table 3) and in IDI but not in
NRI (Table 4).
Sensitivity analyses
The results of the analyses using continuous, log-transformed
values of the different markers are summarized in Tables S3, S4,
S5. On bivariate analysis, IL-6, hs-CRP, leptin and cGT were
positively associated with increased risk of type 2 diabetes; IL-1b
and adiponectin were inversely associated with type 2 diabetes
risk. Conversely, no significant association was found with TNF-a.
After multivariate adjustment, only the positive association with
cGT and the negative association with adiponectin retained their
significance (Table 2).
After stratification on IL-1b levels, no differences were found
regarding the association between IL-6 and incident type 2
diabetes (not shown). When sex-specific quartiles for leptin,
adiponectin and cGT were used no significant improvement was
found in sensitivity, specificity, NPV, PPV and NRI for all the
markers studied (not shown). Similar findings were observed for
most of the different combinations of markers (adiponectin and
CRP, CRP and cGT, and all inflammatory markers, Table S6),
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which did not improve any goodness of fit or predictive capacity
(CRP + cGT) or improved the IDI but improved neither goodness
of fit nor the AUC (CRP and adiponectin). The inclusion of all 7
markers in the model significantly improved the AROC and the
IDI, but not the NRI (Table S6).
Discussion
Our results indicate that low adiponectin levels are associated
with increased risk for type 2 diabetes after adjusting for a
validated type 2 diabetes risk score. Conversely, none of the
markers studied improved prediction compared to the type 2
diabetes risk score, suggesting that these markers, although
associated with type 2 diabetes, do not add clinically useful
information regarding the risk of developing type 2 diabetes.
As a whole, our results suggest that the effect of cytokines (IL-1b,
IL-6 and TNF-a) on the incidence of type 2 diabetes might be
mediated by other factors; they also suggest that these markers do
not improve risk prediction as assessed by a validated type 2 diabetes
risk score. A prospective study suggested that IL-1b might interact
with IL-6, participants with detectable IL-1b levels and elevated IL-
6 levels presenting an increased risk to develop type 2 diabetes
relative to individuals with undetectable IL-1b levels and increased
IL-6 levels [3]. Indeed, after stratification on IL-1b levels, similar
findings were obtained (not shown). Participants who developed
type 2 diabetes had higher baseline IL-6 levels than participants who
did not, but the association was no longer significant after
multivariate adjustment, a finding also reported by others [34].
Finally, no association between TNF-a levels and type 2 diabetes
was found, a finding in agreement with the literature [3,35].
CRP is an inflammatory marker that has been associated with
increased incidence of type 2 diabetes in several studies [2,36],
prompting the inclusion of hs-CRP in a type 2 diabetes risk
prediction score [33]. In this study, a highly significant positive
association was found between hs-CRP levels and incident type 2
diabetes, but this association was no longer significant after
multivariate adjustment, a finding also reported previously [5,37].
Again, adding hs-CRP quartiles to the validated risk score did not
improve risk prediction, suggesting that the effect of hs-CRP on the
development of type 2 diabetes is either mediated by one of the
components of the risk score, or that the independent effect of hs-
CRP is rather small. Further studies are needed to confirm these
findings.
Leptin has been shown to be an independent predictor of type 2
diabetes in some [38,39] but not in all studies [40,41]. Still, some
studies excluded the middle tertile from the analyses [39] and,
most importantly, none of these studies provided information
regarding NRI or IDI as recommended [15,16]. In the present
study, leptin was significantly associated with type 2 diabetes risk
after adjusting for age, gender and BMI, but this association was
no longer significant after adjusting for the type 2 diabetes risk
score. Also, no improvement in the area under the ROC, NRI and
IDI was noted. It is possible that leptin is only one of the several
mediators of obesity or excess adiposity on the incidence of type 2
diabetes [40], so the information for type 2 diabetes risk
assessment provided by assessing leptin levels is smaller than by
assessing adiposity. Another possible explanation is that the Kahn
C+B score includes serum glucose, a strong predictor of risk of
diabetes, which was not available in MONICA/KORA [39].
In the present study, we confirmed that high adiponectin levels
were associated with a lower risk of developing type 2 diabetes, a
finding in agreement with the literature [7,8,42,43]. Conversely,
adding adiponectin to a validated type 2 diabetes risk score led to
no significant improvement in risk prediction, in agreement with a
previous study [44]. Interestingly, in a previous study [43],
adiponectin significantly increased C-index and NRI in one cohort
(FINRISK97) but not in another (Heart 2000), and only the
combination of adiponectin with other markers significantly
improved NRI [43]. Although most of these studies improved
the knowledge of the physiopathology of type 2 diabetes, it
Table 1. Baseline levels of adipocytokine, hepatic and
inflammatory markers for participants who developed type 2
diabetes (n = 208) and those who remained free from it
(n = 3634) after 5 years of follow-up.
Non diabetic
Incident
diabetes P-value
Age (years) 52.1610.5 57.169.5 ,0.001
Women (%) 58.1 31.7 ,0.001
Body mass index (kg/m2) 25.263.9 29.364.2 ,0.001
Interleukin 1b quartiles
First 37.0 43.8
Second 21.3 22.1 0.11
Third 20.9 19.2
Fourth 20.8 14.9
Interleukin 6 quartiles
First 26.0 16.8
Second 25.7 27.9 0.03
Third 24.6 28.4
Fourth 23.6 26.9
Tumour necrosis factor-a quartiles
First 26.0 21.6
Second 25.4 26.4 0.48
Third 24.4 27.9
Fourth 24.2 24.0
hs-CRP quartiles
First 29.2 10.6
Second 25.5 18.7 ,0.001
Third 24.3 30.9
Fourth 21.0 40.4
Leptin quartiles
First 27.5 8.7
Second 26.4 21.6 ,0.001
Third 24.7 22.6
Fourth 21.4 47.1
Adiponectin quartiles
First 23.2 34.1
Second 25.1 27.9 ,0.001
Third 25.3 23.1
Fourth 26.4 14.9
cGT quartiles
First 29.6 10.6
Second 25.1 17.8 ,0.001
Third 24.8 30.8
Fourth 20.5 40.8
LOD, lower limit of detection; CRP, C-reactive protein; cGT, gamma-glutamyl
transpeptidase. Results are expressed as % of column total. Statistical analysis
by Student’s t-test chi-square or Fisher’s exact test.
doi:10.1371/journal.pone.0051768.t001
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remains to be assessed if the increased costs due to biomarker
assessment would be compensated by increased savings due to a
better management of patients at high risk for type 2 diabetes.
Further, a score including adiponectin and other biomarkers as
proposed previously [43] would be difficult to apply in clinical
practice, as it would need to assess different biomarkers in men
and women (ferritin and IL-1 receptor antagonist for women and
CRP and insulin for men). Indeed, in a recent study, about 50%
and 70% of German general practitioners explicitly state not to
use guidelines or risk calculators, respectively [45]. Hence, future
studies should assess not only the importance of new markers in
improving the prediction of type 2 diabetes but also their
applicability in clinical practice and their cost-effectiveness.
A strong positive association between cGT levels and risk of
developing type 2 diabetes was found, and this association persisted
after multivariate adjustment. These findings are in agreement with
the literature [9,10,36,46], suggesting potential interactions between
cGT, enhanced hepatic neoglucogenesis and/or early alterations of
insulin secretion [10,47]. Still, contrary to another study [33],
adding cGT quartiles to the type 2 diabetes risk prediction model
failed to improve prediction, suggesting that cGT assessment might
not be necessary for predicting type 2 diabetes risk in clinical
practice. Still, it will be of interest to evaluate the clinical interest of
Table 2. Association between adipocytokine, hepatic or inflammatory marker levels and incident type 2 diabetes.
Adjusted a P-value Adjusted
b P-value Adjusted c P-value
Quartiles of IL-1b
First 1 (ref) 1 (ref) 1 (ref)
Second 0.95 (0.66–1.38) 0.95 (0.65–1.40) 0.95 (0.62–1.44)
Third 0.86 (0.58–1.27) 0.08 0.79 (0.53–1.18) 0.12 0.72 (0.47–1.10) 0.12
Fourth 0.69 (0.45–1.06) 0.74 (0.48–1.14) 0.74 (0.47–1.18)
Quartiles of IL-6
First 1 (ref) 1 (ref) 1 (ref)
Second 1.54 (1.00–2.39) 1.29 (0.82–2.01) 1.44 (0.89–2.33)
Third 1.58 (1.02–2.45) 0.05 1.22 (0.78–1.92) 0.52 1.14 (0.71–1.84) 0.72
Fourth 1.58 (1.02–2.45) 1.19 (0.75–1.88) 1.18 (0.73–1.93)
Quartiles of TNF-a
First 1 (ref) 1 (ref) 1 (ref)
Second 1.24 (0.82–1.86) 1.21 (0.80–1.85) 1.01 (0.64–1.59)
Third 1.23 (0.82–1.84) 0.87 1.07 (0.70–1.63) 0.39 0.85 (0.54–1.34) 0.054
Fourth 1.04 (0.68–1.59) 0.85 (0.55–1.32) 0.65 (0.41–1.04)
Quartiles of hs-CRP
First 1 (ref) 1 (ref) 1 (ref)
Second 1.91 (1.12–3.26) 1.55 (0.90–2.67) 1.25 (0.70–2.21)
Third 2.88 (1.74–4.75) ,0.001 1.87 (1.12–3.13) ,0.001 1.31 (0.76–2.25) 0.12
Fourth 4.63 (2.85–7.53) 2.35 (1.41–3.93) 1.53 (0.90–2.60)
Quartiles of leptin
First 1 (ref) 1 (ref) 1 (ref)
Second 2.50 (1.43–4.36) 1.91 (1.08–3.35) 1.63 (0.90–2.94)
Third 2.65 (1.52–4.62) ,0.001 1.54 (0.87–2.73) 0.02 0.93 (0.51–1.69) 0.77
Fourth 6.35 (3.79–10.7) 2.23 (1.25–3.98) 1.32 (0.75–2.32)
Quartiles of adiponectin
First 1 (ref) 1 (ref) 1 (ref)
Second 0.68 (0.47–0.98) 0.74 (0.50–1.08) 0.97 (0.64–1.47)
Third 0.54 (0.37–0.80) ,0.001 0.62 (0.41–0.92) ,0.001 0.84 (0.55–1.30) 0.05
Fourth 0.30 (0.19–0.47) 0.41 (0.26–0.65) 0.64 (0.40–1.03)
Quartiles of cGT
First 1 (ref) 1 (ref) 1 (ref)
Second 1.78 (1.04–3.06) 1.39 (0.80–2.41) 1.07 (0.60–1.91)
Third 2.78 (1.69–4.59) ,0.001 1.79 (1.07–3.00) ,0.001 1.13 (0.66–1.94) 0.17
Fourth 4.56 (2.80–7.42) 2.88 (1.75–4.75) 1.45 (0.85–2.46)
IL-1b, interleukin 1-b; IL-6, interleukin-6; TNF-a, tumour necrosis factor-a; CRP, C-reactive protein; cGT, gamma-glutamyl transpeptidase. Data from 208 participants who
developed type 2 diabetes mellitus and 3634 controls. Results are expressed as Odds ratio and (95% confidence interval). Statistical analysis by logistic regression: a,
adjusting for age and gender; b, adjusting for age, gender and body mass index; c, adjusting for Kahn’s clinical and biological score (including age, family history of type
2 diabetes, height, waist circumference, resting heart rate, presence of hypertension, HDL cholesterol, triglycerides, fasting glucose and serum uric acid).
doi:10.1371/journal.pone.0051768.t002
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hepaticmarkers for type 2 diabetes risk prediction, as this assessment
might also be used for other purposes, such as the assessment of
nonalcoholic-fatty-liver-disease [48].
In this study, the effect of each biological marker was assessed
individually, and it has been suggested that the simultaneous
inclusion of several markers might improve risk prediction
[31,32,33]. For instance, a recent study showed that the combined
use of adiponectin and CRP led to an increased risk prediction
[31]. Still, including these two markers simultaneously in the
model did not lead to an improvement in the AROC. Similarly,
adding simultaneously CRP and cGT quartiles as suggested in
another study [33] also led to a non-significant change in AROC
and in the NRI. Another study [43] showed that gender specific
scores including adiponectin and apolipoprotein B (for both
genders), ferritin and IL-1 receptor antagonist (for women) and
CRP and insulin (for men) significantly improved risk prediction
but, as indicated previously, the use of a gender-specific risk score
might not be easy to implement in clinical practice. Further, as no
data was available regarding IL-1 receptor antagonist in our study,
we could not replicate these findings. Finally, a study has shown
that the simultaneous addition of 13 inflammation-related
biomarkers led to a significant improvement in risk prediction
compared to a base model including age, sex and survey [32].
Indeed, including all markers (as quartiles) simultaneously in the
model led to a significant improvement in the AROC and IDI but
failed to improve NRI. Although it can be argued that the risk
improvement was borderline significant, it remains to be assessed if
the evaluation of several different inflammation-related biomark-
ers leads to a sufficient improvement in type 2 diabetes risk
estimation to be cost-effective and easily implemented in clinical
practice.
Our study has several limitations. The participation rate was
low (41%), which might limit the generalization of the findings;
however, this participation rate is similar to other epidemiological
studies [49]. Follow-up time was limited to 5 years; still, a lower
threshold regarding the risk of type 2 diabetes was used to account
for this lower follow-up period. Hence, a 23% risk threshold was
chosen because our follow-up time was only 5 years, which is half
Table 3. Impact of adding different adipocytokine, hepatic or inflammatory markers as quartiles in the predictive capacity of a
clinical + biological (C+B) risk score for type 2 diabetes.
HL-test (p-value) AIC BIC AROC 1 (95% CI) AROC 11 (95% CI)
Kahn’s C+B score 0.84 1123.6 1136.1 0.901 (0.883–0.919) 0.681 (0.648–0.715)
Kahn’s C+B score + IL-1b 0.97 1126.3 1157.6 0.902 (0.884–0.920) 0.692 (0.658–0.726)
Kahn’s C+B score + IL-6 0.96 1127.1 1158.4 0.901 (0.883–0.919) 0.684 (0.650–0.717)
Kahn’s C+B score + TNF-a 0.95 1124.9 1156.2 0.902 (0.883–0.920) 0.686 (0.652–0.720)
Kahn’s C+B score + hs-CRP 0.47 1126.9 1158.2 0.901 (0.883–0.919) 0.686 (0.653–0.720)
Kahn’s C+B score + leptin 0.99 1122.9 1154.2 0.901 (0.883–0.919) 0.682 (0.648–0.715)
Kahn’s C+B score + adiponectin 0.56 1125.4 1156.7 0.902 (0.884–0.920) 0.688 (0.654–0.722)
Kahn’s C+B score + cGT 0.78 1126.5 1157.8 0.902 (0.884–0.920) 0.688 (0.654–0.722)
Kahn’s C+B score + all variables 1.00 1137.9 1281.8 0.908 (0.891–0.925) ** 0.699 (0.665–0.733)
Statistical analysis by logistic regression. Each line shows the results of the original model (first line with HL, Hosmer-Lemeshow goodness-of-fit test (only p-values are
reported); AIC, Akaike’s information criterion; BIC, Bayesian information criterion; AROC, area under the ROC curve; IL-1b, interleukin 1 beta; IL-6, interleukin 6; TNF-a,
tumour necrosis factor alpha; hs-CRP, high sensitive C reactive protein; cGT, gamma glutamyl transpeptidase. 1 using the type 2 diabetes risk predicted by the model as
a continuous variable; 11 splitting the type 2 diabetes risk into two categories (not at risk and at risk). Data from 208 participants who developed type 2 diabetes
mellitus and 3634 controls. ** significantly different (p,0.01) from the baseline model (Kahn’s C+B score).
doi:10.1371/journal.pone.0051768.t003
Table 4. Impact of adding different adipocytokine, hepatic or inflammatory markers as quartiles in the ability of a clinical +
biological risk score to predict type 2 diabetes, using a 23% probability threshold to define high risk subjects.
Sensitivity (%) Specificity (%) PPV (%) NPV (%) NRI (%) IDI (%)
Kahn’s C+B score 40.9 (34.1–47.9) 95.4 (94.6–96.0) 33.6 (27.8–39.8) 96.6 (95.9–97.1) - -
Score + IL-1b 42.8 (36.0–49.8) 95.7 (94.9–96.3) 36.0 (30.0–42.4) 96.7 (96.1–97.3) 2.20 (20.13; 4.53) 0.22 (20.10; 0.55)
Score + IL-6 41.3 (34.6–48.4) 95.4 (94.6–96.0) 33.9 (28.1–40.0) 96.6 (96.0–97.2) 0.48 (22.66; 3.62) 0.00 (20.26; 0.27)
Score + TNF-a 41.8 (35.0–48.8) 95.3 (94.6–96.0) 34.0 (28.2–40.1) 96.6 (96.0–97.2) 0.93 (22.35; 4.22) 0.25 (20.14; 0.63)
Score + hs-CRP 41.8 (35.0–48.8) 95.5 (94.7–96.1) 34.5 (28.7–40.7) 96.6 (96.0–97.2) 1.04 (21.27; 3.36) 0.21 (20.06; 0.48)
Score + leptin 40.9 (34.1–47.9) 95.5 (94.8–96.1) 34.1 (28.3–40.4) 96.6 (95.9–97.1) 0.11 (22.58; 2.80) 0.36 (20.05; 0.78)
Score + adiponectin 41.8 (35.0–48.8) 95.7 (95.0–96.4) 36.0 (29.9–42.3) 96.6 (96.0–97.2) 1.67 (21.96; 4.59) 0.31 (0.00; 0.62)1
Score + cGT 42.3 (35.5–49.3) 95.3 (94.6–96.0) 34.0 (28.2–40.1) 96.7 (96.0–97.2) 1.36 (21.15; 3.87) 0.17 (20.15; 0.49)
Score + all variables 44.2 (37.4–51.3) 95.5 (94.8–96.1) 35.9 (30.1–42.1) 96.8 (96.1–97.3) 3.85 (20.39; 8.09) 2.09 (1.08; 3.10)*
Results are expressed as percentage and (95% confidence interval). PPV, positive predictive value; NPV, negative predictive value; NRI, net reclassification improvement;
IDI, integrated discrimination improvement; IL-1b, interleukin 1 beta; IL-6, interleukin 6; TNF-a, tumour necrosis factor alpha; hs-CRP, high sensitive C reactive protein;
cGT, gamma glutamyl transpeptidase. Data from 208 participants who developed type 2 diabetes mellitus and 3634 controls. 1 p-value 0.052; *, p-value,0.01.
doi:10.1371/journal.pone.0051768.t004
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the 46% threshold proposed by the original Kahn C+B equation,
which was based on a 10 year follow-up. It has been also suggested that
the integrated discrimination improvement might not be a valid tool
for evaluating the capacity of a marker to predict a binary outcome of
interest, because he standard error of the IDI estimate tends to
underestimate the error [50]. This statement actually strengthens our
conclusions, as the confidence intervals for the non-significant IDI
might be even larger than reported. Further, this study was limited to
Caucasian participants and whether the results also apply to other
ethnicities is currently unknown. It has also been stated that NRI is
dependent on cut-off values [51], although this statement has been
challenged [52]. It should also be noted that, despite their inclusion on
recent guidelines [15,16], it has been recently shown that NRI and IDI
interpretation should be made with caution [29,30]. Most biomarkers
studied presented a relatively large intra- and inter-batch variability,
and some also present a large intraindividual variability [53]. This
would lead to an increase in the variance of estimated risk, with a
consequent decrease in discrimination [54]. This might partly explain
the lack of association between some markers and type 2 diabetes after
multivariate adjustment, and it is possible that improvements will be
observed if more stable markers are used. Also, no OGTT were
performed to diagnose type 2 diabetes and no antibodies were
determined to exclude type 1 diabetes either at baseline or at follow-up.
Finally, including in the analyses the 406 participants without leptin
and adiponectin data led to similar conclusions regarding cytokines and
cGT (not shown).
In summary, our results suggest that elevated baseline
adiponectin levels are negatively associated with increased risk
for type 2 diabetes. Still, these markers do not significantly
improve the prediction capacity of an existing, validated type 2
diabetes risk score. Further research should confirm if our findings
also apply to other populations or to other settings. Finally,
additional research on new determinants of type 2 diabetes is of
importance, as it might lead to new therapeutic pathways and/or
to the identification of new prognostic markers of type 2 diabetes.
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